Unmet needs in the scientific approach to older patients with lymphoma

Department of Hematology, Institut Jules Bordet (ULB), Brussels, Belgium; Hematological Malignancies Unit, University Hospital Centre Zagreb, Croatia; Department of Hematology, CHU Dinant Godinne (CHU UCL Namur), Belgium; Department of Hematology, CHU Liège, Belgium; Department of Hematology, Complejo Asistencial Universitario de Salamanca, Spain; Unité de Gériatrie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Université Lyon 1, France; Department of Hematology, Karolinska Institute Huddinge University Hospital Stockholm, Sweden; Institut Bergonié, Bordeaux, France; Lymphoma Unit Division of Research – IOSI / Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; CHU Dinant Godinne (CHU UCL Namur), Belgium and Department of Hematology, Hospices Civils de Lyon, France

[1]  F. Angrilli,et al.  Combination of rituximab and nonpegylated liposomal doxorubicin (R‐NPLD) as front‐line therapy for aggressive non‐Hodgkin lymphoma (NHL) in patients 80 years of age or older: a single‐center retrospective study , 2018, Hematological oncology.

[2]  C. Guillén-Ponce,et al.  Where Are We Headed With Research in Frail Elderly Patients With Cancer? , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Mathoulin-Pélissier,et al.  Detection of frailty in elderly cancer patients: Improvement of the G8 screening test. , 2016, Journal of geriatric oncology.

[4]  I. Floriani,et al.  Estimating the risk of chemotherapy toxicity in older patients with cancer: The role of the Vulnerable Elders Survey-13 (VES-13). , 2015, Journal of geriatric oncology.

[5]  G. Colditz,et al.  Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. , 2015, Journal of geriatric oncology.

[6]  H. Wildiers,et al.  Multicenter implementation of geriatric assessment in Belgian patients with cancer: a survey on treating physicians' general experiences and expectations. , 2014, Journal of Geriatric Oncology.

[7]  R. Stauder,et al.  The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review. , 2014, Leukemia research.

[8]  C. Solid,et al.  Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy , 2014, Supportive Care in Cancer.

[9]  R. Stauder,et al.  The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy , 2014, Annals of Hematology.

[10]  M. D'Andrea,et al.  A retrospective study on 73 elderly patients (≥75years) with aggressive B-cell non Hodgkin lymphoma: clinical significance of treatment intensity and comprehensive geriatric assessment. , 2013, Journal of geriatric oncology.

[11]  F. Peyrade,et al.  Treatment decisions for elderly patients with haematological malignancies: a dilemma. , 2012, The Lancet. Oncology.

[12]  G. Lyman,et al.  Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score , 2012, Cancer.

[13]  M. Pfreundschuh.  How I treat elderly patients with diffuse large B-cell lymphoma. , 2010, Blood.

[14]  B. Coiffier,et al.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.

[15]  P. Solal-Céligny,et al.  Follicular lymphoma international prognostic index , 2006, Blood.

[16]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[17]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.